Provided by Tiger Trade Technology Pte. Ltd.

Scienture Holdings, Inc.

0.1771
-0.0827-31.83%
Post-market: 0.17990.0028+1.58%18:20 EDT
Volume:1.91M
Turnover:362.13K
Market Cap:7.27M
PE:-0.09
High:0.2056
Open:0.2056
Low:0.1760
Close:0.2598
52wk High:2.60
52wk Low:0.1760
Shares:41.06M
Float Shares:32.00M
Volume Ratio:4.47
T/O Rate:5.97%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.0300
EPS(LYR):-2.7049
ROE:-53.47%
ROA:-8.93%
PB:0.11
PE(LYR):-0.07

Loading ...

Top Premarket Decliners

MT Newswires Live
·
Yesterday

Scienture announces reverse stock split

TIPRANKS
·
Yesterday

Scienture Holdings Sets 1-for-25 Reverse Stock Split Effective Oct. 5

Reuters
·
Yesterday

Scienture Holdings, Inc. Announces Reverse Stock Split

THOMSON REUTERS
·
Yesterday

Scienture expands commercial reach of Rexenopy to Addiction Treatment Centers

TIPRANKS
·
Sep 22

Scienture Partners with Distributor to Sell Rezenopy Naloxone Spray to 2,000 US Opioid Treatment Clinics

Reuters
·
Sep 22

Scienture Expands Commercial Reach of Rezenopy™ to Addiction Treatment Centers Through an Agreement with a Distribution Partner

THOMSON REUTERS
·
Sep 22

Scienture - Rezenopy to be Available in About 2,000 Otp Clinics and Addiction Centers in U.S.

THOMSON REUTERS
·
Sep 22

SCIENTURE to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026

GlobeNewswire
·
Sep 09

Scienture Holdings Announces Annual Shareholder Meeting

Reuters
·
Sep 09

Scienture Holdings CFO Eric Sherb Files Initial Beneficial Ownership Statement

Reuters
·
Sep 01

Scienture Holdings Q2 EPS $(0.07) Beats $(0.08) Estimate, Sales $343.639K Miss $1.964M Estimate

Benzinga Earnings
·
Aug 14

Scienture Q2 Revenue Surges on Rezenopy Launch

Reuters
·
Aug 14

Scienture Holdings, Inc Q2 Operating Expenses USD 3 Million

THOMSON REUTERS
·
Aug 14

Scienture Reports Q2 2026 Results with Approximately 510% Sequential Revenue Growth from Q1 2026 and Significant Improvement in Operating Performance

THOMSON REUTERS
·
Aug 14

Scienture Holdings Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 14

Scienture Net Loss Narrows to $2.82 Million in Q2 FY26; Revenue Turns to $343,639

Reuters
·
Aug 14

Scienture Announces Commercial Launch and Fulfillment of Initial Purchase Orders of Rezenopy™, the Highest Dose FDA-Approved Naloxone Nasal Spray

THOMSON REUTERS
·
Aug 12

Scienture Holdings Inc Expected to Post a Loss of 23 Cents a Share - Earnings Preview

Reuters
·
Aug 07

When Will Scienture Holdings, Inc. (NASDAQ:SCNX) Become Profitable?

Simply Wall St.
·
Jul 27